HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy
Background: Zoledronic acid, a bisphosphonate, increases bone mineral density (BMD), which can reduce clinical manifestations in osteogenesis imperfecta. This study investigates the impact of zoledronic acid therapy on the quality of life of pediatric patients with osteogenesis imperfecta. Methods:...
Saved in:
Main Authors: | Tri Wahyu Martanto, Hamzah Rafly Rahman, Patricia Maria Kurniawati |
---|---|
Format: | Article |
Language: | English |
Published: |
Universitas Airlangga
2023-10-01
|
Series: | Journal Orthopaedi and Traumatology Surabaya |
Subjects: | |
Online Access: | https://e-journal.unair.ac.id/JOINTS/article/view/48362 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modern classification and molecular-genetic aspects of osteogenesis imperfecta
by: A. R. Zaripova, et al.
Published: (2020-04-01) -
Dental Findings and Treatment in Osteogenesis Imperfecta: A Case Report
by: Yasemin İspir, et al.
Published: (2024-04-01) -
Efficacy of whole-body vibration on balance and motor function in children with osteogenesis imperfecta: A randomized controlled trial
by: Hanady Abdallah Mouhamed, et al.
Published: (2025-01-01) -
Alendronate partially rescues the periodontal defects in OIM mouse model of osteogenesis imperfecta
by: Po-Jung Chen, et al.
Published: (2025-01-01) -
Challenges in managing osteogenesis imperfecta in a resource-limited setting: a case report
by: Ssekabembe Richard, et al.
Published: (2025-01-01)